DK3322804T3 - Nuklease-uafhængigt målrettet genredigeringsplatform og anvendelser deraf - Google Patents

Nuklease-uafhængigt målrettet genredigeringsplatform og anvendelser deraf Download PDF

Info

Publication number
DK3322804T3
DK3322804T3 DK16825229.4T DK16825229T DK3322804T3 DK 3322804 T3 DK3322804 T3 DK 3322804T3 DK 16825229 T DK16825229 T DK 16825229T DK 3322804 T3 DK3322804 T3 DK 3322804T3
Authority
DK
Denmark
Prior art keywords
nuklease
applications
reduction platform
targeted reduction
independent targeted
Prior art date
Application number
DK16825229.4T
Other languages
English (en)
Inventor
Shengkan Jin
Juan-Carlos Collantes
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57758208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3322804(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Rutgers filed Critical Univ Rutgers
Application granted granted Critical
Publication of DK3322804T3 publication Critical patent/DK3322804T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
DK16825229.4T 2015-07-15 2016-07-15 Nuklease-uafhængigt målrettet genredigeringsplatform og anvendelser deraf DK3322804T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562192876P 2015-07-15 2015-07-15
PCT/US2016/042413 WO2017011721A1 (en) 2015-07-15 2016-07-15 Nuclease-independent targeted gene editing platform and uses thereof

Publications (1)

Publication Number Publication Date
DK3322804T3 true DK3322804T3 (da) 2021-10-04

Family

ID=57758208

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16825229.4T DK3322804T3 (da) 2015-07-15 2016-07-15 Nuklease-uafhængigt målrettet genredigeringsplatform og anvendelser deraf

Country Status (9)

Country Link
US (2) US11479793B2 (da)
EP (2) EP3957731A1 (da)
JP (2) JP7044373B2 (da)
CN (1) CN108291218B (da)
CA (2) CA2992580C (da)
DK (1) DK3322804T3 (da)
ES (1) ES2892625T3 (da)
HK (1) HK1258288A1 (da)
WO (1) WO2017011721A1 (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
JP7044373B2 (ja) 2015-07-15 2022-03-30 ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
CN108513575A (zh) 2015-10-23 2018-09-07 哈佛大学的校长及成员们 核碱基编辑器及其用途
CN107522787A (zh) * 2016-06-15 2017-12-29 中国科学院上海生命科学研究院 在细胞内产生点突变的融合蛋白、其制备及用途
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3565608A4 (en) * 2017-01-05 2020-12-16 Rutgers, The State University of New Jersey TARGETED GENEDITATION PLATFORM INDEPENDENT OF DNA DOUBLE STRAND BREAKAGE AND USES THEREOF
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165631A1 (en) * 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
SG11201908782XA (en) 2017-03-22 2019-10-30 Univ Kobe Nat Univ Corp Method for converting nucleic acid sequence of cell specifically converting nucleic acid base of targeted dna using cell endogenous dna modifying enzyme, and molecular complex used therein
SG11201908658TA (en) 2017-03-23 2019-10-30 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
CN107384920B (zh) * 2017-05-10 2020-07-14 中山大学 一套基于化脓性链球菌的碱基编辑系统及其在基因编辑中的应用
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN110997728A (zh) 2017-05-25 2020-04-10 通用医疗公司 二分型碱基编辑器(bbe)结构和ii-型-cas9锌指编辑
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
CN111263812A (zh) * 2017-07-31 2020-06-09 西格马-奥尔德里奇有限责任公司 用于crispr/cas激活系统的合成的指导rna
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN111757937A (zh) * 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
WO2019099943A1 (en) * 2017-11-16 2019-05-23 Astrazeneca Ab Compositions and methods for improving the efficacy of cas9-based knock-in strategies
CA3089331A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
CN108949830B (zh) * 2018-08-03 2021-11-26 福州大学 一种在鱼类中实现基因组编辑、精确定点基因敲入的方法
CN110878321B (zh) * 2018-09-06 2023-08-22 上海科技大学 一种用于肺炎克雷伯菌基因编辑的表达载体
CN109385425A (zh) * 2018-11-13 2019-02-26 中山大学 一种高特异性ABE碱基编辑系统及其在β血红蛋白病中的应用
EP3921417A4 (en) 2019-02-04 2022-11-09 The General Hospital Corporation ADENINE DNA BASE EDITOR VARIANTS WITH REDUCED OFF-TARGET RNA EDITING
CA3236512A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating hemoglobinopathies
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
US20220235348A1 (en) * 2019-05-15 2022-07-28 Board Of Regents, The University Of Texas System Crispr methods for treating cancers
CA3140093A1 (en) * 2019-05-21 2020-11-26 Beam Therapeutics Inc. Methods of editing a single nucleotide polymorphism using programmable base editor systems
EP4008784A1 (en) * 2019-08-01 2022-06-08 Astellas Pharma Inc. Guide rna for targeted-editing with functional base sequence added thereto
EP3783104A1 (en) * 2019-08-20 2021-02-24 Kemijski Institut Coiled-coil mediated tethering of crispr-cas and exonucleases for enhanced genome editing
CN112481309B (zh) * 2019-09-12 2023-10-10 石家庄埃佤基因科技有限公司 Ago蛋白的用途及组合物和基因编辑方法
US11591607B2 (en) * 2019-10-24 2023-02-28 Pairwise Plants Services, Inc. Optimized CRISPR-Cas nucleases and base editors and methods of use thereof
JP2023504314A (ja) 2019-12-02 2023-02-02 シェイプ セラピューティクス インコーポレイテッド 治療的編集
AU2021231769A1 (en) * 2020-03-03 2022-09-29 The Board Of Trustees Of The Leland Stanford Junior University RNA-guided genome recombineering at kilobase scale
BR112022017704A2 (pt) * 2020-03-04 2022-11-01 Suzhou Qi Biodesign Biotechnology Company Ltd Método e sistema de edição de genoma multiplex
EP4146804A1 (en) 2020-05-08 2023-03-15 The Broad Institute Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2022008935A1 (en) 2020-07-10 2022-01-13 Horizon Discovery Limited Method for producing genetically modified cells
US20230405116A1 (en) * 2020-11-19 2023-12-21 Wake Forest University Health Sciences Vectors, systems and methods for eukaryotic gene editing
US20240067983A1 (en) * 2021-01-05 2024-02-29 Horizon Discovery Limited Guide RNA Designs and Complexes for Tracr-less Type V Cas Systems
WO2022148955A1 (en) 2021-01-05 2022-07-14 Horizon Discovery Limited Method for producing genetically modified cells
EP4274903A1 (en) * 2021-01-05 2023-11-15 Horizon Discovery Limited Guide rna designs and complexes for type v cas systems
GB202107671D0 (en) 2021-05-28 2021-07-14 Asociacion Centro De Investig Cooperativa En Nanociencias Cic Nanogune Synthetic cas proteins
EP4347808A2 (en) 2021-05-25 2024-04-10 ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN NANOCIENCIAS "CIC nanoGUNE" Synthetic cas proteins
WO2024096790A1 (en) * 2022-10-31 2024-05-10 Soledits Ab Modular crispr system
CN116726198B (zh) * 2023-03-13 2024-02-13 陕西师范大学 一种抗肿瘤药物及其在脑胶质瘤治疗中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US63258A (en) 1867-03-26 David king
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US5061641A (en) 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US20100063258A1 (en) 2006-06-28 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Fusion protein constructs
DK2476689T3 (da) 2007-05-10 2016-01-18 Agilent Technologies Inc Thiocarbonbeskyttende grupper til RNA-syntese
US20110104787A1 (en) 2009-11-05 2011-05-05 President And Fellows Of Harvard College Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
DK3401400T3 (da) 2012-05-25 2019-06-03 Univ California Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering
PT2864360T (pt) 2012-06-25 2018-01-05 The Brigham And Women`S Hospital Inc Terapêuticas dirigidas ao alvo
CN105658796B (zh) 2012-12-12 2021-10-26 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3553174A1 (en) 2012-12-17 2019-10-16 President and Fellows of Harvard College Rna-guided human genome engineering
JP2016506541A (ja) 2012-12-18 2016-03-03 レンズヴェクター インコーポレイテッドＬｅｎｓｖｅｃｔｏｒ Ｉｎｃｏｒｐｏｒａｔｅｄ 高度な電界制御能力を備えた液晶光学装置
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
CA2907198C (en) 2013-03-15 2019-12-10 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
EP4245853A3 (en) 2013-06-17 2023-10-18 The Broad Institute, Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
US9068179B1 (en) * 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
EP3080271B1 (en) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
EP3985124A1 (en) * 2013-12-26 2022-04-20 The General Hospital Corporation Multiplex guide rnas
MX2016010285A (es) * 2014-02-11 2017-01-11 Univ Colorado Regents Ingenieria genetica multiplexada habilitada por crispr.
CN111471674A (zh) * 2014-03-05 2020-07-31 国立大学法人神户大学 特异性转变靶向dna序列的核酸碱基的基因组序列的修饰方法、及其使用的分子复合体
WO2016054106A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California SCAFFOLD RNAs
PT3221457T (pt) 2014-11-21 2019-06-27 Regeneron Pharma Métodos e composições para modificação genética visada através da utilização de arn guia emparelhados
JP7044373B2 (ja) 2015-07-15 2022-03-30 ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
CN108513575A (zh) 2015-10-23 2018-09-07 哈佛大学的校长及成员们 核碱基编辑器及其用途
EP3565608A4 (en) 2017-01-05 2020-12-16 Rutgers, The State University of New Jersey TARGETED GENEDITATION PLATFORM INDEPENDENT OF DNA DOUBLE STRAND BREAKAGE AND USES THEREOF
EP4380627A1 (en) 2021-08-06 2024-06-12 Rutgers, the State University of New Jersey Method for producing genetically modified cells

Also Published As

Publication number Publication date
ES2892625T3 (es) 2022-02-04
WO2017011721A1 (en) 2017-01-19
CA2992580C (en) 2022-09-20
JP2018520686A (ja) 2018-08-02
US20180327784A1 (en) 2018-11-15
EP3322804B1 (en) 2021-09-01
JP7364268B2 (ja) 2023-10-18
CN108291218B (zh) 2022-08-19
CA2992580A1 (en) 2017-01-19
JP7044373B2 (ja) 2022-03-30
EP3322804A1 (en) 2018-05-23
EP3957731A1 (en) 2022-02-23
HK1258288A1 (zh) 2019-11-08
US20220267806A1 (en) 2022-08-25
CN108291218A (zh) 2018-07-17
CA3168241A1 (en) 2017-01-19
EP3322804A4 (en) 2019-01-30
JP2022095633A (ja) 2022-06-28
US11479793B2 (en) 2022-10-25

Similar Documents

Publication Publication Date Title
DK3322804T3 (da) Nuklease-uafhængigt målrettet genredigeringsplatform og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3872085T3 (da) Stam-virussekvenser og anvendelser heraf
DK3368534T3 (da) Valbenazin-ditosylat og polymorfer deraf
DK3310371T3 (da) Glucagon og GLP-1-Co-agonistforbindelser
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3201351T3 (da) Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
DK3265947T3 (da) Fremgangsmåde og system til kryptering
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3155024T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
DK3157552T3 (da) Syntac-polypeptider og anvendelser deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3395801T3 (da) Arylazolforbindelse og skadedyrsbekæmpelsesmiddel
DK3256598T3 (da) Svampestammer og anvendelsesfremgangsmåder
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3054744T3 (da) Lederforbindelse og lederforbindelseskomponent
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
MA49905A (fr) Polyesteramines et polyesterquats
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf